Changing What’s Possible in Equine & Animal Care Through advanced photonic technology designed to support health and vitality
Click here to be a part of the #RU4It Campaign!Photonic Corpuscular Irradiation (PCI-1) is an innovative, light-based technology developed to eradicate pathogens that cause diseases in Equine, Bovine and other Farm & Domestic Animals. Designed with both veterinarians and animal owners in mind, PCI-1 offers a novel approach for animals that may not have responded optimally to conventional treatment methods.
Bacterial Diseases GONE:
Common Bacterial Diseases:
-
Horses are affected by many infectious diseases, including bacterial causes like Streptococcus equi (strangles), Salmonella, Clostridium species, Rhodococcus equi, and others — and these can lead to significant illness and death in some cases.
-
For example, Strangles — a well-known contagious bacterial disease — is estimated to have a mortality rate around 8.1% in affected horses.
-
Severe bacterial complications like sepsis in horses are known to carry a very high fatality rate (often reported at 60–70% in affected cases)
Fungal Diseases GONE:
Common Fungal Diseases include:
-
The respiratory system (e.g., guttural pouch mycosis, aspergillosis)
-
Skin and hooves (e.g., dermatophytosis / “ringworm”)
-
Eyes (fungal keratitis — particularly dangerous)
-
Systemic infections (rare, but very serious)
Viral Diseases GONE:
Other Diseases GONE:
Common Equine Viral Diseases Include:
-
Equine Influenza
-
Equine Herpesvirus (EHV-1, EHV-4) — including neurologic forms
-
West Nile Virus
-
Eastern & Western Equine Encephalitis
-
Equine Viral Arteritis
- Equine Herpes Virus
Common Equine Diseases NOT in the Above Categories Include:
- Anhidrosis – Sweating Sickness
- Fevers of unknown origin
- Allergies
- Sores & Lesions
- Rashes
- Equine Prozonan Myeloencephelitis (EPM)
- Eastern Equine Encephalitis (EEE)
Click on the image to go to the “RU4It” page to get involved!
Our Story
Where It All Began
Breakthrough Discovery in the Treatment of The Corona Virus, HIV/AIDS, and other Catastrophic Diseases.
Fifteen years ago, Dr. Danilo Fernandez discovered an innovative way of treating all types of viral, bacterial, fungal, and parasitic diseases that afflict both humans and animals.
In 2002 he designed a Blood Irradiation machine that treats the blood in such a way that it eliminates all pathogens from the bloodstream without any morphological changes or damage to the blood
Introducing
Photonic Corpuscular Irradiation (PCI-1)
PCI-1 excites (or irradiates) a small amount of blood, that when it is re-introduced into the body and it recirculates throughout the bloodstream, it destroys viruses, bacteria, fungi, and parasites. No resistance is developed by the pathogens and, no damage is done to the body or the delicate biomes, as with Antibiotics. In the case of Organically raised animals this eliminates the issues of not being able to sell the animals as “Organic” when treated with antibiotics.
GlobalMed Technologies (GMTUSA) has developed this unique, patented, world-changing biomedical process that works in both humans & animals.
Update
Current Situation
The Situation
Globally there have been over 79 million reported cases of COVID19 with more than 1.7 million deaths since the start of the pandemic. (WHO)
Urgency
The world is at an unprecedented impasse collecting scientific data as rapidly as possible to enable a treatment process that will stop the onslaught of COVID19 infections. Operation Warp Speed is in effect with the goal to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (countermeasures).
Vaccines
42% of U.S. adults say they would not get a vaccine and an unknown % of the overall population will have severe allergic reactions to the vaccines. Additionally, people with an allergy to PEG or polysorbate are being told not to get an mRNA COVID-19 vaccine. For this and other reasons, an alternative treatment to this life threatening virus is urgently needed.
Our Purpose
GlobalMed Technologies (GMT) is dedicated to making their PCI treatment readily available to people all over the world, from all walks of life, that are either refusing or allergic to antiretrovirals, We can increase the quality of these people’s lives with our treatment.
Current Clinical Trials
Over the next few days and weeks, GMT will sponsor several phased clinical trials including adults with confirmed COVID19 in the US.
Where we’ve been
History of GlobalMed
In 2003, Dr. Danilo Fernandez received a U.S. patent for his product and process. In 2004 a government-approved, Phase I Controlled Clinical Trial was conducted on 36 Human patients with acute and chronic HIV/AIDS. These patients’ viral loads were reduced by 85 to 99% and their CD4-cells (T-helper cells) were stabilized and reduced. Most importantly, 100% of opportunistic infections (OIs) were eliminated and none of these patients were given anti-viral medications, either prior to or during the trial. Between 2006 and 2009, GMT completed an additional pilot study on 7 patients, in order to prove and repeat the results achieved in Phase I. GMT not only surpassed earlier results but also showed that the 7 Chronic HIV patients (who had been hospitalized between 5 to 7 times a year in the past) did not require hospitalization or any anti-retroviral medications, for the duration of the 29-month study.